T
he American Heart Association's Get With The Guidelines-Stroke (GWTG-Stroke) program has been developed to measure and improve the quality of care and outcome for patients hospitalized with stroke. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The program provides via performance achievement awards public recognition of hospitals with high performance on select performance measures for acute ischemic stroke. These measures of achievement include intravenous (IV) tissue plasminogen activator (tPA) within 3 hours (if symptoms onset to door is within 2 hours), use of antithrombotics, timing of antithrombotics, anticoagulation for atrial fibrillation, deep venous thrombosis prophylaxis, low-density lipoprotein (LDL) <100 mg/dL or statin treatment for patients with LDL ≥100 mg/dL, and smoking cessation counseling. Performance on these achievement measures has reached a high level. 1, 2 In contrast, performance on several other quality measures that were not utilized as part of the hospital recognition criteria has been poor. 1 In order to further improve stroke care, the GWTG-Stroke program expanded its recognition program by creating the Plus Awards in 2009. This program provides an added incentive by recognizing hospitals meeting 75% compliance on any 4 additional quality measures. The additional measures are dysphagia screening, stroke education, consideration of rehabilitation, door to tPA time within 1 hour, documentation of LDL cholesterol, intensive statin therapy, last known well to IV tPA time within 4.5 hours if onset to door is less than 3.5 hours, and reporting of the National Institutes of Health Stroke Severity Score.
We sought to evaluate the impact of the Plus awards on quality of stroke care for hospitals participating in GWTGStroke. We tested the hypothesis that performance on the quality measures for stroke improved at a faster rate following implementation of the Plus award program than prior to the Plus awards. In addition, we sought to exclude any unintended, negative impact on the pre-existing stroke performance measures following the launch of the PLUS awards.
Methods
GWTG-Stroke is a national voluntary stroke registry and performance improvement initiative from the American Heart Association. In GWTG-Stroke, participating hospitals use an internet-based patient management tool (Quintiles, Cambridge, MA) to collect data on consecutive acute ischemic stroke patients. The methods and quality auditing for GWTGStroke have been previously described in detail.
Plus Award Intervention
Prior to the introduction of the Plus Awards, 12 the recognition program for the GWTG-Stroke (Achievement Award) publically acknowledged hospitals reaching 85% compliance with each of the following measures: IV tPA within 3 hours (if last known well to IV tPA time is within 2 hours), early antithrombotics, appropriate antithrombotics, anticoagulation for atrial fibrillation, deep venous thrombosis prophylaxis, LDL cholesterol <100 mg/dL or statin treatment for patients with LDL ≥100 mg/dL, and smoking cessation counseling. For a hospital to also be recognized by the new Plus Award Program, they must both receive the established Achievement Award, and demonstrate 75% compliance for 12 consecutive months on 4 out of 8 stroke quality measures: dysphagia screening, stroke education, consideration of rehabilitation, door to tPA time within 1 hour, documentation of LDL cholesterol, intensive statin therapy, use of IV tPA by , patients who died prior to discharge (N=140 460), and patients who were transferred to other healthcare facilities or left against medical advice (N=792 117). Patients who died, transferred, or left against medical advice were older, were more likely to be female, and more likely to have comorbid conditions (Table S1 ). The primary analysis included 1 149 732 acute ischemic stroke patients from 1224 participating hospitals.
Outcomes
The primary outcomes were use of the quality measures in appropriate candidates. We excluded 2 measures with 12 months or less of pre-award data available (stroke education and intensive statin therapy). The 6 measures included in the analysis were dysphagia screening, consideration of rehabilitation, door to tPA time within 1 hour, documentation of LDL cholesterol, use of IV tPA by 4.5 hours if onset to door is within than 3.5 hours, and reporting of the National Institutes of Health Stroke Severity Score. A defect-free composite quality measure was also created.
All GWTG-Stroke participating institutions were required to comply with local regulatory and privacy guidelines and, if required, to secure institutional review board approval. Sites were granted a waiver of informed consent under the common rule as data were used primarily at the local site for quality improvement. The Duke Clinical Research Institute (Durham, NC) served as the data analysis center, and institutional review board approval was granted to analyze aggregate deidentified data for research purposes.
Statistical Analysis
Patient and hospital characteristics were summarized descriptively for the preprogram and postprogram periods. Standardized mean differences were calculated for the preand postaward periods. Piecewise (or segmented) logistic multivariable regression models were performed to track the trends over time of achievement measures in pre-, and post-Plus periods. The adjusted models account for differing hospital and patient characteristics over time. Characteristics included were (1) patient demographics: age, sex, race; (2) medical history: atrial fibrillation, prosthetic heart valve, previous stroke or transient ischemic attack, coronaPry artery disease or prior myocardial infarction, carotid stenosis, peripheral vascular disease, hypertension, dyslipidemia, and smoking; (3) hospital characteristics: annual stroke admission, bed size, region, hospital type (academic versus not), primary stroke center, urban/rural location. For each outcome, we provide the odds ratio (with 95% CI and P-value) per 3 calendar months as the rate of improvement during the preprogram period, the odds ratio (with 95% CI and P-value) per 3 months after program initiation, and a P value comparing these to evaluate if the rate of improvement significantly changed after program initiation. Both unadjusted and adjusted odds ratios and CIs are reported. The generalized estimating equation method with exchangeable working correlation matrix was applied to provide valid inference after accounting for the within-site correlation. 13 Hospital characteristics were missing in <1%, and patients from these hospitals were excluded in multivariable models. All P values are 2-sided, with P<0.05 considered statistically significant. Analyses were performed using SAS software (version 9.2; SAS Institute, Cary, NC). 
Results
The Tables 1 and 2 . In general, differences in patient and hospital characteristics over time were small though often statistically significant because of the large sample size.
Quality Metrics and Plus Awards
Use of the 6 quality metrics are shown over time in Figure 1A Compliance with all quality metrics use was considerably higher for patients hospitalized at the Plus Award facilities (Table 3) . For hospitals recognized with the Plus Award compared to those not recognized, the absolute difference in quality measure performance ranged from 24.7% for use of IV tPA within 4.5 hours in patients arriving within 3.5 hours of last known well to 4.3% for assessed for rehabilitation (Table 3) . Performance improved for all quality metrics after initiation of the Plus Award program.
Quality Measured by the Relative Increase in Use
The unadjusted and adjusted rates of increase per quarter for the preprogram period (January 2008-June 2009) were compared with the established program period (January 2010-December 2013) for the 6 quality measures (Table 4) . Adjustment had little impact on the observed odds ratios and confidence intervals. The odds ratio for receiving the recommended care increased significantly more rapidly for 1 measure in the post-Award period than the pre-Award period (IV tPA within 60 minutes), at a similar rate for 3 measures, and more slowly during the post-Award period than during the pre-Award period for 2 measures. For the defect-free composite measure, the rate of improvement was less in the post-Award period.
Quality Measured by the Relative Decrease in Gap in Care
When the yearly decrease in the quality gap (100%-baseline use) was averaged over the 3 pre-Plus years and compared with the 4 post-Plus years (Figure 2 ), 5 of 6 measures (as well as the composite measure) showed an acceleration in the average annual quality gap reduction following the launch of the Plus Awards.
Impact on Established Measures of Quality
There was no evidence of adverse impact on the established achievement measures ( Figure 3A and 3B). Those hospitals receiving the new award (Plus Sites) had better performance on the established Achievement Measures (Table 3 ).
Discussion
We evaluated the impact of expanding the recognition program of the American Heart Association's GWTG-Stroke
Program. We found that performance on the targeted measures improved after launch of the program and the performance of those hospitalized recognized with the Plus Award was considerably better than those not recognized. The rate of change in improvement did not increase for most measures. In fact, we found that the rate of improvement over time was slower for 2 measures and faster for 1 measure following the launch of the Plus awards than in the period before the Plus Awards. However, when measured as the relative decrease in the gap in care, the program was associated with most of the processes improving at an accelerated rate following launch of the program. These findings demonstrate that the Plus Awards were effective in providing recognition for hospitals with superior performance on the quality measures that were the focus of the awards criteria. Those hospitals receiving the Plus Awards provided higher quality care as measured by all the quality measures compared to those hospitals not recognized. During the postaward period, clinically relevant improvements were observed in the performance for each quality measure. However, the relative rates of improvement in the postaward period were increased only for the IV tPA within 60-minute measure, which was the focus of a separate focused performance improvement initiative Target Stroke, 14,15 which remained similar for 3 measures, and actually decelerated for 2 quality measures. There are several potential explanations for the decrease in the rate of improvement following the launch of the awards. Each of the process metrics has a ceiling at 100%, and "room" for additional improvement continually decreases as care improves. If changes in performance over time were small compared to the gap in care (current versus ideal state), then the examination of rates of change over time may reflect an impact of an intervention. However, we found that care was improving rapidly prior to the launch of the Plus awards. Thus, the impact of ceiling effects may have occurred regardless of the initiation of Plus awards.
Our findings provide guidance for those wishing to evaluate a new intervention when contemporaneous controls are not possible. If quality is stable or only slowly improving, then an analysis of rate of change over time may detect moderate or greater effects of an intervention. However, if the gap in care is rapidly decreasing at baseline, it may not be possible to 
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detect an incremental effect of any intervention. Measuring the decrease in the "care gap" may be more revealing if the process use is already over 50%.
Our results are consistent with a prior evaluation of the GWTG-Heart Failure enhanced Award program. 16 After the American Heart Association expanded their recognition program by adding additional heart failure quality measures, the investigators noted that care improved. However, as with the current analysis of stroke care, the rate of improvement in heart failure care did not increase after enhancement of the heart failure recognition program. Those metrics that were at a relatively low level prior to launch increased more rapidly than those metrics that were at a higher baseline level.
Other reasons for a slowed rate of increase following the launch of the Plus awards include that the GWTG-Stroke Performance Achievement Award remained the primary motivator for quality improvement even though compliance was already at a high level. Achievement measures usually have a stronger evidence base compared to quality measures that may also contribute to the hospitals' higher level of compliance for Achievement than quality measures. In contrast to the Performance Achievement Award recognition, the Plus awards may not have provided sufficient incentive for hospitals to focus additional meaningful performance improvement efforts on these processes. The hospitals may have felt that an additional award had insufficient value to devote resources to change practice. It is also possible the way the Plus Award recognition program was structured, with the option of which measures to select for recognition, was less effective for facilitating process improvement. The impact of any recognition program may be weakened by strong financial incentives being implemented by many payers including Medicare that began during the study (eg, readmissions reduction), but did not specifically involve patients hospitalized with stroke. 17 One concern of expanding the number of measures used for recognition or pay for performance is that they will detract from existing measures. In our study there was the potential that hospitals would focus less on the more established (and important) quality measures for stroke care by redirecting resources toward improving the quality measures that were part of the expanded recognition program. However, our results do not provide any evidence of such an effect, as the existing Achievement measures also improved with the launch of the expanded program.
Limitations
There are several potential limitations of this study. The American Heart Association's use of the Plus Award program was nonrandomized, nor did it have a contemporaneous control. The baseline rates of use were often rapidly increasing at the time of the program launch, making it difficult to determine the incremental impact of the program. In addition, the time duration between pre and post measurement may be too short to detect important differences because of the Plus Award Program. The quality measures evaluated by the new recognition program were already reported, privately, to the individual hospitals. Hospitals participating in GWTG-Stroke may be more interested in quality improvement than other hospitals, and these hospitals may have already focused on many of the quality metrics. An additional award may have been a minimal incentive for these higher-performing hospitals. The GWTG-Stroke program is voluntary, and it is not clear whether an award program would have a similar impact if hospitals were mandated to participate.
In summary, we found that an expanded recognition program for the quality of stroke care, while providing recognition to hospitals with superior performance on quality measures, did not have a clear impact on accelerating improvements in care. While care improved compared to baseline, the rate of care improvement slowed for some measures. Importantly, the assessment of the program's impact was different if quality was measured as the relative increase in use or the relative decrease in nonuse (gap in care). Our findings demonstrate the difficulty in interpreting the impact of hospital or provider incentives when contemporaneous controls are not feasible.
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